Research Article

Estradiol (E2) Reduction Adversely Affect the Embryo Quality and Clinical Outcomes of In Vitro Fertilization and Embryo transfer (IVF-ET)

Table 4

Comparison of the stimulation variables and clinical outcomes between the spontaneously falling E2 group and the drug dosage reduction group.

VariablesSpontaneously reduction (n = 63)Dose-adjusted reduction (n = 57) value

Starting dosage of Gn used (IU)156.55 ± 49.23174.55 ± 56.510.068
Duration of Gn used (d)16.38 ± 4.3813.37 ± 2.66<0.001
Total dosage of Gn used (IU)3147.22 ± 1448.742250.32 ± 888.53<0.001
Endometrial thickness on hCG day (mm)11.07 ± 2.4111.11 ± 1.900.920
LH level on the hCG day (IU/L)0.59 ± 0.580.56 ± 0.360.744
E2 level on the hCG day (pg/ml)1517.31 ± 936.482330.37 ± 1296.09<0.001
P level on the hCG day (ng/mL)0.54 ± 0.300.60 ± 0.310.284
Number of oocytes retrieved (n)11.19 ± 5.5014.77 ± 5.460.001
Rate of high-quality embryos (%)0.77 ± 0.260.81 ± 0.200.299
Blastocysts available rate (%)0.40 ± 0.300.51 ± 0.280.053
Clinical pregnancy rate (%)61.90% (39/63)54.39% (31/57)0.404
Early abortion rate (%)17.95% (7/39)19.35% (6/31)0.881
Ongoing pregnancy rate (%)50.79% (32/63)43.86% (25/57)0.448
Live birth rate (%)47.62% (30/63)38.60% (22/57)0.319

hCG, human chorionic gonadotropin; Gn, gonadotropin.